2015
Impact on Patient Management and Outcome of Switching between 2 Contemporary Sensitive Cardiac Troponin Assays
Wilen CB, Szymanski JJ, Hung S, Rajan A, Lavigne PM, Char DM, Geltman EM, Scott MG. Impact on Patient Management and Outcome of Switching between 2 Contemporary Sensitive Cardiac Troponin Assays. Clinical Chemistry 2015, 61: 870-876. PMID: 25886769, DOI: 10.1373/clinchem.2015.238089.Peer-Reviewed Original ResearchCriteria for Reducing Unnecessary Testing for Herpes Simplex Virus, Varicella-Zoster Virus, Cytomegalovirus, and Enterovirus in Cerebrospinal Fluid Samples from Adults
Wilen CB, Monaco CL, Hoppe-Bauer J, Jackups R, Bucelli RC, Burnham CA. Criteria for Reducing Unnecessary Testing for Herpes Simplex Virus, Varicella-Zoster Virus, Cytomegalovirus, and Enterovirus in Cerebrospinal Fluid Samples from Adults. Journal Of Clinical Microbiology 2015, 53: 887-895. PMID: 25568435, PMCID: PMC4390640, DOI: 10.1128/jcm.03161-14.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCerebrospinal FluidCohort StudiesCosts and Cost AnalysisCytomegalovirusEnterovirusHerpesvirus 3, HumanHumansLeukocyte CountLeukocytes, MononuclearMeningitis, AsepticMiddle AgedMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesRetrospective StudiesSensitivity and SpecificitySimplexvirusConceptsNucleic acid amplification testingVaricella-zoster virusCerebrospinal fluid samplesHSV-1/2Unnecessary testingHerpes simplex virus 1/2Retrospective observational studyCells/Fluid samplesComputerized order setsHerpes simplex virusHealth care costsNAAT assaysImmunocompetent adultsImmunocompetent subjectsValidation cohortAmplification testingObservational studyPositive testCSF samplesEV testingSimplex virusLimited followClinical specificityCare costs
2010
A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5
Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW. A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5. Journal Of Virology 2010, 84: 10863-10876. PMID: 20702642, PMCID: PMC2950574, DOI: 10.1128/jvi.01109-10.Peer-Reviewed Original ResearchMeSH KeywordsBase SequenceBinding SitesCCR5 Receptor AntagonistsCell LineCohort StudiesCyclohexanesDNA PrimersDrug Resistance, ViralHIV Envelope Protein gp120HIV Fusion InhibitorsHIV InfectionsHIV-1HumansIn Vitro TechniquesMaravirocModels, BiologicalMutant ProteinsMutationPeptide FragmentsProtein Structure, TertiaryReceptors, CCR5TriazolesConceptsCCR5 antagonistsLow CCR5 levelsTreatment-experienced patientsPlasma viral RNACCR5 antagonist maravirocCourse of treatmentHigh-level resistanceMVC resistanceMVC treatmentVirologic failureExtracellular loopCCR5 levelsTreatment regimensCross-resistance profilesCXCR4 useV3 loopCCR5 useHIV entryHIV-1Viral envelope proteinsCCR5V4 loopsAntagonistMaravirocPatients